Gene editing may one day cure the oral herpes virus. Here's why that virus is tough to tackle and how to prevent and minimize ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.90.

Graham Parry, an analyst from Bank of America Securities, maintained the Sell rating on GlaxoSmithKline (GSK – Research Report). The associated ...

Objective To quantify changes in inequalities in uptake of childhood vaccination during a period of steadily declining overall childhood vaccination rates in England. Design Longitudinal study.

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

GSK respiratory/immunology research and development global head Kaivan Khavandi stated: “Working with Relation enables us to ...

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

Pharmaceutical and biotech businesses were enthusiastic about the UPC before the court opened, but so far there has only been ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Netflix, Inc. (NFLX), BP p.l.c. (BP) ...

London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate top-line Phase 2b data in rheumatoid arthritis in ...